TY - JOUR
T1 - Clinical utility of the GAD-7 for detecting generalized anxiety in Quechua indigenous people
AU - Caldichoury, Nicole
AU - Quispe-Ayala, César
AU - Coronado, Juan Carlos
AU - Castellanos-Alvarenga, Luis Mario
AU - Salazar, David
AU - Morales-Asencio, Breiner
AU - Ripoll-Córdoba, Daniela
AU - Quincho-Apumayta, Raúl
AU - Cárdenas-Valverde, Juan
AU - Camargo, Loida
AU - Alcos-Flores, Karen
AU - Layme-Condori, Eloy
AU - Villalba-Arbañil, Rosa
AU - Castellanos, Cesar
AU - Gargiulo, Pascual A.
AU - Quispe-Rodríguez, Indalecio
AU - Muñoz-Romero, Elsa
AU - Patiño-Rivera, Alberto Rivelino
AU - Flores-Poma, Irina
AU - Herrera-Pino, Jorge
AU - López, Norman
N1 - Publisher Copyright:
Copyright © 2025 Caldichoury, Quispe-Ayala, Coronado, Castellanos-Alvarenga, Salazar, Morales-Asencio, Ripoll-Córdoba, Quincho-Apumayta, Cárdenas-Valverde, Camargo, Alcos-Flores, Layme-Condori, Villalba-Arbañil, Castellanos, Gargiulo, Quispe-Rodríguez, Muñoz-Romero, Patiño-Rivera, Flores-Poma, Herrera-Pino and López.
PY - 2025
Y1 - 2025
N2 - The detection of Generalized Anxiety Disorder (GAD) in indigenous populations poses a challenge due to their holistic approach to health, which significantly contrasts with the Western biomedical model. Moreover, conventional assessment tools often overlook cultural particularities, compromising their effectiveness in these contexts. Objective: Therefore, this study aimed to analyze the diagnostic accuracy of the GAD-7 in the Quechua indigenous population of the Peruvian Andes. Method: To address this issue, we conducted a case-control study to evaluate the clinical accuracy of the Generalized Anxiety Disorder Test (GAD-7) in rural Quechua communities of the Peruvian Andes. We included 147 GAD patients and 322 controls. The study involved four stages: cultural adaptation of the GAD-7, door-to-door evaluation, blind psychiatric and neuropsychological assessments, and application of the Quechua GAD-7. The adaptation used the Delphi method, focus groups, and bilingual judges. Factor analyses, reliability assessments, and diagnostic utility evaluations were performed. Results: The Quechua GAD-7 showed high content validity (Aiken’s V > 0.85), strong internal consistency (α = 0.912, ω = 0.85), and an area under the curve of 0.93. With a cutoff score of 11, it achieved 91.3% sensitivity and 86.1% specificity. Conclusions: This is the first study to validate a Western test for GAD in indigenous populations.
AB - The detection of Generalized Anxiety Disorder (GAD) in indigenous populations poses a challenge due to their holistic approach to health, which significantly contrasts with the Western biomedical model. Moreover, conventional assessment tools often overlook cultural particularities, compromising their effectiveness in these contexts. Objective: Therefore, this study aimed to analyze the diagnostic accuracy of the GAD-7 in the Quechua indigenous population of the Peruvian Andes. Method: To address this issue, we conducted a case-control study to evaluate the clinical accuracy of the Generalized Anxiety Disorder Test (GAD-7) in rural Quechua communities of the Peruvian Andes. We included 147 GAD patients and 322 controls. The study involved four stages: cultural adaptation of the GAD-7, door-to-door evaluation, blind psychiatric and neuropsychological assessments, and application of the Quechua GAD-7. The adaptation used the Delphi method, focus groups, and bilingual judges. Factor analyses, reliability assessments, and diagnostic utility evaluations were performed. Results: The Quechua GAD-7 showed high content validity (Aiken’s V > 0.85), strong internal consistency (α = 0.912, ω = 0.85), and an area under the curve of 0.93. With a cutoff score of 11, it achieved 91.3% sensitivity and 86.1% specificity. Conclusions: This is the first study to validate a Western test for GAD in indigenous populations.
KW - GAD-7 test
KW - Quechua
KW - case-control study
KW - clinical utility
KW - rural indigenous
UR - https://www.scopus.com/pages/publications/105007975519
U2 - 10.3389/fpsyt.2025.1565895
DO - 10.3389/fpsyt.2025.1565895
M3 - Artículo
AN - SCOPUS:105007975519
SN - 1664-0640
VL - 16
JO - Frontiers in Psychiatry
JF - Frontiers in Psychiatry
M1 - 1565895
ER -